The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) reversed a prior negative decision and recommended approval for Eli Lilly’s Alzheimer's drug Kisunla for certain patient groups. This development increases the likelihood of the drug entering the European market. Additionally, CHMP endorsed Gilead’s twice-yearly HIV prevention injection among other decisions. These recommendations mark pivotal regulatory milestones that could influence treatment options across neurodegenerative and infectious disease sectors in Europe.